Immediate Impact

2 by Nobel laureates 4 from Science/Nature 54 standout
Sub-graph 1 of 24

Citing Papers

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
2023 Standout
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
2022 Standout
1 intermediate paper

Works of Mark R. Bowles being referenced

Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by Human Liver Carboxylesterase
1996

Author Peers

Author Last Decade Papers Cites
Mark R. Bowles 346 77 67 145 21 541
Yue-Li Sun 238 38 66 220 21 510
Jane Hamlett 270 41 96 124 27 605
Keun Na 352 44 51 86 25 611
Gaëlle Noé 235 24 58 184 25 584
Stefan Müllner 337 63 17 143 30 641
Anthony J. Chubb 278 62 107 78 24 599
D E Pollet 217 83 93 85 16 581
Robert G. Pietrusko 197 35 28 122 15 588
J. E. Sodergren 268 31 35 119 12 559
Jingchun Gao 320 20 47 139 19 595

All Works

Loading papers...

Rankless by CCL
2026